Scarica l'app Stockscreener
24.85
0.65%
0.16
Dopo l'orario di chiusura:
24.86
0.010
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.69
Aprire:
$24.72
Volume 24 ore:
40.65M
Relative Volume:
0.84
Capitalizzazione di mercato:
$141.29B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
13.22
EPS:
1.8799
Flusso di cassa netto:
$12.44B
1 W Prestazione:
+1.35%
1M Prestazione:
+3.41%
6M Prestazione:
+12.75%
1 anno Prestazione:
-14.10%
Intervallo 1D:
$24.60
$24.96
Intervallo di 1 settimana:
$24.16
$24.96
Portata 52W:
$20.91
$29.17
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.85 | 140.38B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
799.57 | 725.20B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.88 | 466.54B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
231.39 | 409.95B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.34 | 255.13B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.62 | 215.61B | 63.43B | 16.42B | 14.72B | 6.4861 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Does the Recent 3% Gain Signal a Turning Point for Pfizer Shares? - simplywall.st
mRNA Therapeutics and Global Markets to 2030, Profiles of Leading CompaniesModerna, Pfizer, BioNTech, Merck, and SanofiResearchAndMarkets.com - The AI Journal
Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ - The Globe and Mail
2 Mega-Dividend Stocks With Yields As High As 7% - The Globe and Mail
Pfizer (PFE) Receives a Hold from Wells Fargo - The Globe and Mail
Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Relay Therapeutics (RLAY) - The Globe and Mail
Pfizer's Phase 3 Success and GSK's Rollout Expansion Spark Momentum in the Global Malaria Vaccine Market - openPR.com
Lobbying Update: $2,730,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
What analyst consensus implies for Pfizer Inc. (PFE) stockWeekly Profit Report & Capital Efficient Trade Techniques - nchmf.gov.vn
Will Pfizer Inc. (Common Stock) (PFEB) stock deliver stable dividends2025 Analyst Calls & Accurate Entry and Exit Point Alerts - nchmf.gov.vn
How Pfizer Inc. stock performs in volatility spikesJuly 2025 Retail & Technical Pattern Based Buy Signals - nchmf.gov.vn
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect - sharewise.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider - GlobeNewswire Inc.
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Canc - GuruFocus
PFIZER INC : JP Morgan sticks Neutral - MarketScreener
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer
Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener
40.3% lower risk of death — XTANDI + leuprolide raises 8‑yr OS to 78.9% in nmHSPC (Pfizer) - Stock Titan
Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire
Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS
What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn
How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer
Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener
Will Pfizer Inc. (PFE) stock deliver compounding returns2025 Key Highlights & Reliable Price Action Trade Plans - nchmf.gov.vn
Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda - MarketScreener
Why Pfizer Inc. stock is considered a top pick2025 Top Decliners & Free Growth Oriented Trading Recommendations - nchmf.gov.vn
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients - MarketScreener
Will Pfizer Inc. stock attract ESG investorsJuly 2025 Sector Moves & Smart Money Movement Tracker - nchmf.gov.vn
Did Pfizer Overpay For Yet Another Acquisition? (NYSE:PFE) - Seeking Alpha
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential (NYSE:PFE) - Seeking Alpha
How Pfizer Inc. (Common Stock) (PFEB) stock behaves under inflation pressure2025 Volatility Report & Low Risk Profit Maximizing Plans - nchmf.gov.vn
Will Pfizer Inc. stock split again soonJuly 2025 PreEarnings & AI Enhanced Execution Alerts - nchmf.gov.vn
Energy Moves: Is Pfizer Inc. stock a buy on dipsJuly 2025 Sector Moves & AI Driven Price Forecasts - nchmf.gov.vn
Can Pfizer Inc. (PFE) stock deliver strong annual returnsQuarterly Trade Review & Consistent Income Trade Recommendations - nchmf.gov.vn
Dow Update: Is Pfizer Inc. stock a good choice for value investors2025 Year in Review & Technical Pattern Based Signals - nchmf.gov.vn
Is Pfizer Inc. stock a good choice for value investorsMarket Sentiment Review & Weekly Watchlist of Top Performers - nchmf.gov.vn
RSI Check: Is Pfizer Inc. stock positioned well for digital economy2025 Market Trends & Step-by-Step Trade Execution Guides - nchmf.gov.vn
Can Pfizer Inc. (PFE) stock retain market dominance2025 Key Lessons & Long-Term Growth Stock Strategies - nchmf.gov.vn
Why Pfizer Inc. stock attracts high net worth investorsPrice Action & Reliable Breakout Forecasts - nchmf.gov.vn
Risk Off: Is Pfizer Inc. stock a good choice for value investors2025 Key Highlights & Entry Point Confirmation Signals - nchmf.gov.vn
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer - TipRanks
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):